Background: Sex differences in the outcomes after percutaneous coronary intervention with drug-eluting stents and in the response to clopidogrel therapy have been reported; however, the differential risk of high platelet reactivity (HPR) on clopidogrel in women versus men is unknown.
Methods And Results: We compared 8448 patients enrolled in the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) according to sex and the presence/absence of HPR on clopidogrel (defined as P2Y12 reactivity units >208). Study end points were definite and probable stent thrombosis (ST), clinically relevant bleeding, all-cause mortality, myocardial infarction, and major adverse cardiac events (comprising mortality, myocardial infarction, and target lesion revascularization). HPR was more common among women (1118/2163, 51.7%) than men (2491/6285, 39.6%). HPR was associated with a roughly double risk of 1-year ST in both women and men (women with versus without HPR: 1.4% versus 0.7%; hazard ratio [HR], 2.02; 95% confidence interval [CI], 0.82-4.95; =0.12; and men: 1.2% versus 0.5%; HR, 2.42; 95% CI, 1.36-4.30; =0.002; =0.73). HPR was associated with almost half the rate of clinically relevant bleeding in women (women: HPR versus no HPR, 5.3% versus 9.8%; HR, 0.54; 95% CI, 0.40-0.74; <0.001), whereas men had similar rates of bleeding regardless of HPR status (men: HPR versus no HPR, 5.7% versus 5.9%; HR, 0.96; 95% CI, 0.78-1.18; =0.70; =0.003). In propensity-adjusted models, HPR was an independent predictor of ST and myocardial infarction in men; although both associations were nonsignificant among women, no interaction was observed in the associations between HPR and either ST or myocardial infarction. Conversely, HPR was an independent predictor of reduced bleeding only in women (women: adjusted HR, 0.58; 95% CI, 0.41-0.82; =0.002; and men: adjusted HR, 0.83; 95% CI, 0.65-1.04; =0.11; =0.01).
Conclusions: In the current analysis, the associated risk of HPR for ST was similar in both sexes. However, HPR was associated with significantly reduced bleeding only among women.
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00638794.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCINTERVENTIONS.116.003577 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional Mechanical Behavior and Biocompatible Characteristics of Graphene-Coated Cardiovascular Stents.
Int J Mol Sci
December 2024
Pre-Clinical Research Centre, Wrocław Medical University, Marcinkowskiego 1, 50-368 Wrocław, Poland.
Percutaneous Coronary Intervention (PCI) is a treatment method that involves reopening narrowed arteries with a balloon catheter that delivers a cylindrical, mesh-shaped implant device to the site of the stenosis. Currently, by applying a coating to a bare metal stent (BMS) surface to improve biocompatibility, the main risks after PCI, such as restenosis and thrombosis, are reduced while maintaining the basic requirements for the mechanical behavior of the stent itself. In this work, for the first time, the development and optimization process of the spatial structure of the Co-Cr stent (L-605) with a graphene-based coating using cold-wall chemical vapor deposition (CW-CVD) to ensure uniform coverage of the implant was attempted.
View Article and Find Full Text PDFImpact of coronary artery tortuosity on outcomes following stenting with newer-generation drug-eluting stents. An analysis of the randomized BIOFLOW trials.
Rev Esp Cardiol (Engl Ed)
January 2025
Department of Cardiology, Internal Medicine II, Medical University of Vienna, Vienna, Austria. Electronic address:
Introduction And Objectives: Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent.
Methods: A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe.
Baicalin-based composite coating for achieving biological multifunctionality of vascular stents.
J Control Release
January 2025
Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, PR China. Electronic address:
Article Synopsis
- Vascular stents are crucial for treating atherosclerosis and have reduced mortality through bare metal and drug-eluting options, but concerns like restenosis and thrombus formation persist.
- Hyaluronic acid (HA) is often used to modify stent surfaces, but its effectiveness is limited due to degradation by reactive oxygen species (ROS) and enzymes, which can provoke inflammation and affect stent performance.
- The study introduces a new coating using baicalin (BCL) to protect HA from degradation, offering enhanced endothelial cell support and greater stability, positioning this method as a promising advancement in stent technology.
Recurrent drug eluting stent, in-stent restenosis (DES-ISR): Epidemiology, pathophysiology & treatment.
Prog Cardiovasc Dis
January 2025
Division of Cardiovascular Medicine, Department of Medicine, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22909, United States of America. Electronic address:
Coronary artery in-stent restenosis (ISR) is driven by neointimal hyperplasia and neoatherosclerosis in previously placed stents. Drug eluting stents (DES) have been adopted as first line therapy for the initial episode of ISR. However, recurrent ISR has limited durable salvage options.
View Article and Find Full Text PDFNovel Use of Drug-eluting Stent in Otologic Surgery to Prevent Restenosis.
Ann Otol Rhinol Laryngol
January 2025
Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Objectives: The primary objective of this case series is to assess the effectiveness of the off-label use of the PROPEL drug-eluting stent, traditionally FDA-approved for sinus surgery, in preventing restenosis following canalplasty in patients with chronic otologic conditions or congenital anomalies. The stent provides both mechanical support to maintain canal patency and localized steroid delivery to reduce inflammation and scarring.
Methods: Four patients with various otologic conditions underwent canalplasty, followed by the placement of drug-eluting stents into the external auditory canal.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!